MDACC Study No:2005-0099 ( NCT No: NCT00147225)
Title:Phase I/II Study of AMG 531 in Patients with Advanced Malignancy Receiving Treatment with Chemotherapy
Principal Investigator:Saroj Vadhan-Raj
Treatment Agent:Adriamycin; AMG 531; Carboplatin; Ifosfamide
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest safe dose of
AMG 531 that will decrease the risk and severity of thrombocytopenia (low
platelet counts) in patients who have received chemotherapy. Researchers will
also look at the safety and effectiveness of AMG 531 (Romiplostim).
Hide details for General InformationGeneral Information

Disease Group:Gastrointestinal; Genitourinary; Gynecology; Head And Neck; Sarcoma
Phase of Study:Phase I/Phase II
Treatment Agents:Adriamycin
AMG 531
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Clinic visits prior to each cycle (approximately every 3 weeks).
Home Care:Routine labs, management of myelosuppression and supportive care.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Saroj Vadhan-Raj
Dept:Cytokines and Supportive Care
For Clinical Trial Enrollment:713-792-7966
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults